Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$1.95 USD
+0.02 (1.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CGTX 1.95 +0.02(1.04%)
Will CGTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGTX
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
CGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGTX
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
Cognition Therapeutics provided recap of virtual KOL event
12 Health Care Stocks Moving In Monday's After-Market Session
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)